DIPROLENE OINTMENT

Country: Kanada

Lingwa: Ingliż

Sors: Health Canada

Ingredjent attiv:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE)

Disponibbli minn:

ORGANON CANADA INC.

Kodiċi ATC:

D07AC01

INN (Isem Internazzjonali):

BETAMETHASONE

Dożaġġ:

0.05%

Għamla farmaċewtika:

OINTMENT

Kompożizzjoni:

BETAMETHASONE (BETAMETHASONE DIPROPIONATE) 0.05%

Rotta amministrattiva:

TOPICAL

Unitajiet fil-pakkett:

15G/50G

Tip ta 'preskrizzjoni:

Prescription

Żona terapewtika:

ANTI-INFLAMMATORY AGENTS

Sommarju tal-prodott:

Active ingredient group (AIG) number: 0106299002; AHFS:

L-istatus ta 'awtorizzazzjoni:

APPROVED

Data ta 'l-awtorizzazzjoni:

2011-03-02

Karatteristiċi tal-prodott

PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
DIPROLENE
®
betamethasone dipropionate ointment, Organon Standard
0.05% W/W
Topical Corticosteroid
ORGANON CANADA INC.
Date of Initial Approval
16766 route Transcanadienne
January 07, 1985
Kirkland, Quebec
H9H 4M7
Date of Revision:
April 13, 2021
www.organon.ca
Control
#
:
249779
2
PRODUCT MONOGRAPH
NAME OF DRUG
DIPROLENE
®
betamethasone dipropionate ointment 0.05% W/W
PHARMACOLOGICAL CLASSIFICATION
Topical corticosteroid
ACTIONS
DIPROLENE
®
provides anti-inflammatory, antipruritic and vasoconstrictive effects.
The propylene
glycol components of the vehicle increase penetration and enhance the
local effectiveness of
betamethasone dipropionate.
INDICATIONS AND CLINICAL USES
DIPROLENE
®
is indicated for the relief of the inflammatory manifestations of
resistant or severe
psoriasis and corticosteroid-responsive dermatoses.
CONTRAINDICATIONS
DIPROLENE
®
is contraindicated in viral diseases including vaccinia, varicella,
herpes simplex, and
fungal infections; also, tuberculosis of the skin. DIPROLENE
®
products are contraindicated in those
patients with a history of sensitivity reactions to betamethasone
dipropionate, other corticosteroids or
to any of the components of DIPROLENE
®
products.
WARNINGS
Do not use in or near the eyes since DIPROLENE
®
is not formulated for ophthalmic use. This product
should not be used under occlusive dressing.
3
Any of the side effects that are reported following systemic use of
corticosteroids, including adrenal
suppression, may also occur with topical corticosteroids, especially
in infants and children.
Pregnancy and lactation: Since safety of topical corticosteroid use in
pregnant women has not been
established, drugs of this class should be used during pregnancy only
if the potential benefit justifies
the potential risk to the fetus. Drugs of this class should not be
used extensively in large amounts or for
prolonged periods of time in pregnant patients.
Since it is not known whether topical administration of
cortic